Karelizumab often refers to karelizumab for injection, a drug that does not currently treat cholangiocarcinoma. Injectable Karelizumab is a human immunoglobulin G4 monoclonal antibody, which can bind to PD-1 receptor, block its interaction with PD-L1 and PD-L2, and block PD-1 pathway-mediated immunosuppressive response, including anti-tumor immune response, which can inhibit tumor growth. Currently karelizumab is mainly used for: 1. patients with relapsed or refractory classical Hodgkin’s lymphoma who have undergone at least second-line systemic chemotherapy; 2. patients with advanced hepatocellular carcinoma who have previously received sorafenib treatment and/or oxaliplatin-containing systemic chemotherapy; 3. non-surgically resectable locally advanced or metastatic non-squamous non-small cell lung cancer; 4. patients with locally advanced or metastatic squamous esophageal cancer with disease progression or intolerable disease after receiving prior first-line chemotherapy; 5. patients with advanced nasopharyngeal carcinoma who have previously received second-line or higher chemotherapy with disease progression or intolerable; 6. Combination of cisplatin and gemcitabine for patients with locally recurrent or metastatic nasopharyngeal carcinoma. Cholangiocarcinoma is a malignant tumor of the hepatobiliary system originating from the epithelial cells of the bile ducts. Depending on the indication, the drug is not usually used to treat cholangiocarcinoma. If cholangiocarcinoma is suspected or diagnosed, it is recommended to go to regular hospitals for comprehensive assessment of the condition, integrating multiple means to diagnose and evaluate the disease, and cooperate with the treatment as prescribed by the doctor, so as to avoid delaying the condition. Please strictly follow the doctor’s prescription for drug treatment, and do not use drugs on your own.